Aurobindo Pharma is increasing its ownership in its China joint venture Luoxin Aurovitas Pharma (Chengdu) Co. Ltd through its wholly owned Dutch subsidiary, Helix Healthcare B.V., by acquiring an additional 20 per cent stake for about USD 5.12 million in cash.
Financial indicators for Luoxin Aurovitas show growth in recent years, with the entity reporting a turnover of USD 2.34 million in the fiscal year 2024-25, up from USD 0.48 million in FY 2023-24, and a net worth of USD 15.29 million as of September 30, 2025, reflecting steady expansion of its operations.
This move will raise Helix’s share in the venture from 30 per cent to 50 per cent within the next three months, strengthening Aurobindo’s strategic presence in the Chinese pharmaceutical manufacturing landscape. Luoxin Aurovitas Pharma, established in March 2019 as a 30:70 joint venture with China’s Shandong Luoxin Pharmaceutical Group Stock Co. Ltd, focuses on the production of inhalation products for the Chinese market.
The increased stake is aimed at expanding the company’s manufacturing capacity by adding two high-speed production lines to achieve greater economies of scale and meet rising market demand for inhalation therapies.
Under the terms of the agreement, Helix Healthcare has secured the right to acquire the remaining 50 per cent stake by December 2029 at a pre-agreed price of USD 18.86 million, subject to certain conditions. No regulatory approvals are required for the stake acquisition.
Also Read